Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma

Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rafael Roesler, Barbara Kunzler Souza, Gustavo R. Isolan
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	epidermal growth factor receptor ErbB biomarker meningioma intracranial tumor Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/cf5a5bd28c35447baf38e34d1f7122fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf5a5bd28c35447baf38e34d1f7122fc
record_format	dspace
spelling	oai:doaj.org-article:cf5a5bd28c35447baf38e34d1f7122fc2021-11-11T16:49:44ZReceptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma10.3390/ijms2221113521422-00671661-6596https://doaj.org/article/cf5a5bd28c35447baf38e34d1f7122fc2021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11352https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM.Rafael RoeslerBarbara Kunzler SouzaGustavo R. IsolanMDPI AGarticleepidermal growth factor receptorErbBbiomarkermeningiomaintracranial tumorBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11352, p 11352 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	epidermal growth factor receptor ErbB biomarker meningioma intracranial tumor Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	epidermal growth factor receptor ErbB biomarker meningioma intracranial tumor Biology (General) QH301-705.5 Chemistry QD1-999 Rafael Roesler Barbara Kunzler Souza Gustavo R. Isolan Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
description	Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM.
format	article
author	Rafael Roesler Barbara Kunzler Souza Gustavo R. Isolan
author_facet	Rafael Roesler Barbara Kunzler Souza Gustavo R. Isolan
author_sort	Rafael Roesler
title	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
title_short	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
title_full	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
title_fullStr	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
title_full_unstemmed	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
title_sort	receptor tyrosine kinases as candidate prognostic biomarkers and therapeutic targets in meningioma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cf5a5bd28c35447baf38e34d1f7122fc
work_keys_str_mv	AT rafaelroesler receptortyrosinekinasesascandidateprognosticbiomarkersandtherapeutictargetsinmeningioma AT barbarakunzlersouza receptortyrosinekinasesascandidateprognosticbiomarkersandtherapeutictargetsinmeningioma AT gustavorisolan receptortyrosinekinasesascandidateprognosticbiomarkersandtherapeutictargetsinmeningioma
_version_	1718432266602938368

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma

Ejemplares similares